Sunesis Pharmaceuticals (SNSS) Reports Strong Q1 Results
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Join SI Premium – FREE
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported Q1 EPS of $0.04, $0.18 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $4 million, versus $13 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- 374Water Inc (SCWO) Misses Q2 EPS by 15c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
